Core Insights - GSK's shares have increased by approximately 8% since the last earnings report, outperforming the S&P 500 [1] - The company reported core earnings of 59 cents per American depositary share (ADS), exceeding the Zacks Consensus Estimate of 53 cents, although core earnings declined by 20% year-over-year [2] - Quarterly revenues rose by 1% to $10.4 billion (£8.12 billion), surpassing the Zacks Consensus Estimate of $10.00 billion [2] Segment Performance - Specialty Medicines segment saw a 17% increase in sales, driven by strong growth in HIV, Immunology/Respiratory, and Oncology [5] - General Medicines sales increased by 6%, supported by strong demand for the asthma inhaler Trelegy Ellipta [14] - Vaccine sales declined by 12%, primarily due to lower sales of the RSV vaccine Arexvy and shingles vaccine Shingrix [16] Specialty Medicines Details - HIV sales rose by 14%, with significant contributions from the dolutegravir franchise, which saw an 8% increase in sales [5][6] - New long-acting medicines Cabenuva and Apretude experienced sales growth of 43% and 65%, respectively, contributing over 50% to total HIV growth [7] - Oncology sales surged by 72%, driven by strong demand for Jemperli and Ojjaara [8] General Medicines Insights - Trelegy Ellipta sales surged by 17%, while sales of established drugs like Advair/Seretide declined by 2% [14] - General Medicines sales are expected to remain stable in 2025, with volume growth offset by pricing pressures [15] Vaccine Performance - Arexvy sales fell by 69% year-over-year, while Shingrix sales decreased by 4% due to lower demand [16][17] - Meningitis vaccine Bexsero sales rose by 39%, while Menveo sales declined by 41% [19] Financial Outlook - GSK expects sales growth of 3-5% in 2025, with Specialty Medicines driving this growth [21] - The company plans to buy back up to £2 billion of shares over the next 18 months [22] - A dividend of 64p is planned for 2025, reflecting a 5% increase year-over-year [23] Long-Term Guidance - GSK raised its long-term sales outlook for 2031 to over £40 billion, up from a previous estimate of over £38 billion [24] - Specialty Medicines are expected to account for more than 50% of sales by 2031 [24] - The company maintained its guidance for 2021-2026, expecting sales growth of more than 7% and core operating profit growth of more than 11% on a CAGR basis [25]

Investment Rating - The investment rating for the pharmaceutical industry is "Outperform the Market" (maintained) [1] Core Insights - The main growth driver remains the launch of innovative products, particularly in the GLP-1 category, with significant revenue increases reported by companies like Eli Lilly and Novo Nordisk [3] - The report highlights the strong performance of key products across various therapeutic areas, including oncology, metabolism, and immunology, with notable sales growth percentages [3] Summary by Sections 01 Overview of Overseas Pharmaceutical Companies Q4 2024 and Annual Performance - Eli Lilly's revenue increased by 32% in 2024, driven by GLP-1 products [3] - Novo Nordisk's sales reached approximately $40.5 billion, a 25% increase, with significant contributions from GLP-1 products [29] - AstraZeneca and Merck also reported strong growth, with revenue increases of 21% and 10% respectively [3] 02 Performance Review of Overseas Pharmaceutical Companies - Eli Lilly's Q4 sales reached $13.5 billion, a 45% increase, with GLP-1 products contributing significantly [18] - Novo Nordisk's GLP-1 products achieved sales of approximately $22.5 billion, with a 20% increase in the diabetes segment [29] - JNJ's pharmaceutical segment reported $14.3 billion in Q4, with oncology products driving growth [40] R&D Investment - The top 15 pharmaceutical companies invested over $150 billion in R&D in 2024, a 7% increase year-on-year, with a research expense ratio of 21.8% [8] Sales Performance in China - Seven overseas pharmaceutical companies reported combined sales of approximately 515 billion RMB in Q4 2024, with a year-on-year growth of 10% [14]

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=134353&wire=4GSK in ...

Core Viewpoint - GSK plc is facing allegations related to misleading statements regarding the withdrawal of Zantac from the market, with claims that the company was aware of the source of NDMA for nearly 40 years before the product's removal [1]. Group 1: Allegations and Legal Context - The class period for the allegations against GSK spans from February 5, 2020, to August 14, 2022 [1]. - Defendants allegedly misrepresented to investors that GSK removed Zantac based on available information and correspondence with regulators, while also claiming that there was no evidence linking ranitidine therapy to cancer [1]. - The complaint asserts that GSK's representations were materially false or misleading, as the company had prior knowledge of the NDMA source [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action, with a deadline set for April 7, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [3].

Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misled investors regarding the removal of Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of GSK plc American Depositary Receipts (ADRs) about a class action lawsuit related to misleading statements made by GSK regarding the withdrawal of Zantac from the market and its implications for investors [1][4][5]. Group 1: Class Action Details - The class action pertains to GSK ADRs purchased between February 5, 2020, and August 14, 2022, with a lead plaintiff deadline of April 7, 2025 [1][2]. - Investors who purchased GSK ADRs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Allegations Against GSK - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac, claiming it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [4][5]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later revealed to be misleading as they had concealed an internal study implicating their liability [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, highlighting its track record in securities class actions and significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].

On Monday, the Food and Drug Administration (FDA) accepted for review GSK plc’s GSK marketing application for depemokimab in two indications.The company released topline data from the trials in October 2024.The proposed indications are as add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller and, as add-on maintenanc ...

Financial Performance - GSK's group sales reached £31.4 billion in 2024, reflecting a 3% increase AER and 7% increase CER, with a 4% growth AER and 8% CER excluding COVID-19 sales[69] - The company reported a corporate income tax payment of £1.3 billion, alongside other taxes, demonstrating its economic contribution[41] - GSK plans to buy back £2 billion of shares over the next 18 months, aiming to enhance shareholder returns[78] - A full year dividend of 61p was declared for 2024, with an expected increase to 64p in 2025[77] Research and Development - The company reported a £6.4 billion investment in R&D for 2024, focusing on innovative medicines and vaccines[35] - R&D expenditure exceeded £6 billion in 2024, with £2.3 billion allocated to targeted business development[80] - GSK achieved 13 positive phase III clinical trial readouts in 2024, marking a record for GSK[74] - GSK has 71 assets in development, with 13 positive phase III readouts and 23 approvals or regulatory filings in the past year[111][117] - GSK's phase III development cycle times are now in the top quartile for the industry, reflecting increased productivity in R&D[117] - The company is leveraging advanced technologies, including AI, to enhance the R&D process and improve the effectiveness of drug discovery[37] Specialty Medicines and Oncology - GSK achieved strong growth across its Specialty Medicines business, with sales growth in Respiratory/Immunology, Oncology, and HIV franchises at AER and CER[45] - Specialty Medicines now account for nearly 40% of GSK's total sales, driven by strong growth in Respiratory/Immunology, which saw a 9% increase AER and 13% increase CER[70] - Oncology sales nearly doubled to over £1.4 billion, with significant contributions from new treatments for ovarian and endometrial cancers[72] - Projected global spending on oncology medicines is expected to reach $440 billion by 2028, indicating a growing market for novel cancer treatments[100] Vaccines and Preventative Healthcare - GSK's vaccines portfolio targets infectious diseases at every stage of life, contributing to its broad market presence[35] - GSK's RSV vaccine, Arexvy, received expanded approvals in adults aged 50-59, demonstrating sustained efficacy over three RSV seasons[125] - The company is focusing on preventative healthcare, with adult immunization potentially returning up to 19 times its initial investment through health and socio-economic benefits[104] - Shingrix, the shingles vaccine, demonstrated 82% efficacy within the 11th year post-vaccination, with over 73% cumulative efficacy from year 6 to 11 for individuals over 70[208] - The MenABCWY vaccine candidate for meningitis has been accepted for regulatory review by the US FDA, aiming to simplify immunization and increase vaccination rates[210] Corporate Strategy and Impact - GSK aims to positively impact the health of 2.5 billion people by the end of the decade, having reached an estimated 2 billion patients from 2021 to 2024[44] - The company emphasizes the importance of its purpose to get ahead of disease, aligning with changing population demographics and disease patterns[48] - GSK's commitment to responsible business practices is reflected in its leadership position in the Access to Medicine Index, maintaining a top ranking since 2008[83] Product Development and Approvals - Five new product approvals are expected in 2025, including treatments for multiple myeloma and severe asthma[75] - The company executed 12 acquisitions and discovery collaborations in 2024, including the acquisition of Elsie Biotechnologies to enhance its oligonucleotide pipeline[120] - Nucala (mepolizumab) is the only treatment in the US and Europe with indications in four IL5 mediated diseases, with new approvals in Japan and China for chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma[143][144] - The FDA expanded approval for Jemperli to include all patients with primary advanced or recurrent endometrial cancer, covering approximately 75% of diagnosed patients[168] - A phase II study of dostarlimab in locally advanced dMMR rectal cancer showed all 42 patients had no evidence of disease after treatment[170] Market Trends and Industry Insights - The biopharma industry completed approximately 60 AI/ML focused deals in 2024, with a total deal value of £9.9 billion[95][96] - China's share of global biopharma companies increased to 16% in 2024, while the US holds the largest share at 39%[95] - GSK anticipates a series of major product launches from 2025 onwards, with peak year sales projected to exceed £2 billion[118]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 79 New Oxford Street, London, WC1A 1DG (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. ●Cas ...

Core Viewpoint - GSK plc is facing a class action lawsuit due to allegations of misleading statements regarding the withdrawal of Zantac from the market and the knowledge of its potential cancer-causing ingredient, NDMA [1][2]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [1]. - Allegations state that GSK misrepresented its reasons for removing Zantac, claiming it acted based on available information and regulatory correspondence, while being aware of NDMA's source for nearly 40 years [1]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later found to be materially false or misleading [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased GSK shares during the specified period are encouraged to register for the class action by April 7, 2025 [2]. - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [3].